New horizons in migraine treatment
Seize the opportunity to offer your patients an innovative and effective treatment method for managing migraine symptoms together with CEFALY®.
The first therapeutic choice for the acute and preventive treatment of migraine
(CE marked & FDA aproved)
Acute migraine treatment (ACME study)
Percentage of patients who no longer feel pain after 1 hour
>50% pain reduction after 1 hour
Neuromodulation 2017: Chou, D. E., Gross, G. J., Casadei,
C. H., & Yugrakh, M. S. (2017). External Trigeminal Nerve
Stimulation for the Acute Treatment of Migraine: Open-Label
Trial on Safety and Efficacy. Neuromodulation: Technology at the
Neural Interface.
Cephalalgia 2019: Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial.
Preventive Migraine Treatment (PREMICE Study)
Migraine reduction
Response rate
Neurology 2013: Schoenen, J., Vandersmissen, B.,
Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P.,
& Magis, D. (2013). Migraine prevention with a
supraorbital transcutaneous stimulator: A randomized
controlled trial. Neurology, 80(8), 697-704.
Safety: Prospective study with 2313 patients
Side effects occur in only 4.3% of all patients compared to an
average of 50% for typical
oral migraine oral use of migraine medications as part of a
preventive as part of a preventive treatment.
We are here for you
We look forward to your interest in CEFALY® and are available for product
demonstrations.
![](https://www.cefaly.ch/media/03/0a/6a/1696716057/cefaly-team-sibylle-zeller.jpg)
Sibylle Zeller
Sales & Account Manager
![](https://www.cefaly.ch/media/4c/bd/54/1701178406/IMG_9244.jpg)
Adele Fanelli
Sales & Account Manager
![](https://www.cefaly.ch/media/f5/b1/ee/1701178430/IMG_9922.jpg)
Daniel Leemann
Sales & Product Application
![](https://www.cefaly.ch/media/e8/a1/32/1701178445/IMG_1691.jpg)
Lucas Heider
Sales & Product Application